Search

Your search keyword '"Eltrombopag -- Intellectual property"' showing total 9 results
Start Over Descriptor "Eltrombopag -- Intellectual property"
9 results on '"Eltrombopag -- Intellectual property"'

1. Delhi High Court orders in favour of Novartis AG's patent on eltrombopag olamine

Subjects
India. High Court of Delhi, Novartis AG -- Intellectual property, Eltrombopag -- Intellectual property, Pharmaceutical industry -- Intellectual property, Pharmaceuticals and cosmetics industries
Abstract

Byline: Gireesh Babu The Delhi High Court has issued a permanent injunction against two Indian companies protesting Novartis AG's patent for eltrombopag olamine, an active pharmaceutical ingredient (API) in its [...]

Published
2022

2. Delhi HC restrains Natco from dealing with Novartis' patented API containing eltrombopag olamine

Subjects
Novartis AG -- International economic relations -- Intellectual property, Natco Pharma Ltd. -- International economic relations -- Intellectual property, Eltrombopag -- Intellectual property, Pharmaceutical industry -- International economic relations -- Intellectual property, Pharmaceuticals and cosmetics industries
Abstract

Byline: Laxmi Yadav The Delhi High Court has restrained Natco Pharma Limited from importing, selling, offering for sale, exporting, or dealing directly or indirectly in any active pharmaceutical ingredient containing [...]

Published
2021

3. Patent Issued for Liposomal compositions with light illumination-induced drug release (USPTO 11154619)

Subjects
Carboplatin -- Intellectual property, Eltrombopag -- Intellectual property, Methylene blue -- Intellectual property, Antineoplastic agents -- Intellectual property, Amino acids -- Intellectual property, Antimitotic agents -- Intellectual property, Health
Abstract

2021 NOV 17 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the [...]

Published
2021

4. Patent Application Titled 'Liquid Biopsy Yield Enhancement' Published Online (USPTO 20210263032)

Subjects
Carboplatin -- Intellectual property, Eltrombopag -- Intellectual property, Palifermin -- Intellectual property, Lanreotide, Antineoplastic agents -- Intellectual property, Enzyme inhibitors -- Intellectual property, Trifluridine -- Intellectual property, Palonosetron -- Intellectual property, Monoclonal antibodies, BCR-ABL tyrosine kinase inhibitors, Antimitotic agents -- Intellectual property, Business, Health, Health care industry
Abstract

2021 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2021

5. Researchers Submit Patent Application, 'Smart Dosing For Cancer Therapy', for Approval (USPTO 20210193332)

Subjects
Carboplatin -- Intellectual property, Palifermin -- Intellectual property, Disodium pamidronate -- Intellectual property, Nilotinib, Antineoplastic agents -- Intellectual property, Cancer -- Care and treatment -- Research, Rasburicase -- Intellectual property, Antimitotic agents -- Intellectual property, Oncology, Experimental, Eltrombopag -- Intellectual property, Zoledronic acid, Aprepitant -- Intellectual property, Vaccines -- Intellectual property, Palonosetron -- Intellectual property, Monoclonal antibodies, Health
Abstract

2021 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors INWALD, David [...]

Published
2021

6. Patent Issued for Dose And Regimen For HDM2-P53 Interaction Inhibitors (USPTO 10,966,978)

Subjects
Novartis AG -- Intellectual property, Eltrombopag -- Intellectual property, Tumor proteins, Pharmaceutical industry -- Intellectual property, Business, Health, Health care industry
Abstract

2021 APR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Novartis AG (Basel, Switzerland) has been issued patent number 10,966,978, according to news reporting originating [...]

Published
2021

7. Patent Application Titled 'Solid State Forms Of Eltrombopag Choline' Published Online (USPTO 20200331862)

Subjects
Tromethamine -- Intellectual property, Chemical industry -- Intellectual property, Chemicals -- Intellectual property, Choline -- Intellectual property, Eltrombopag -- Intellectual property, Health
Abstract

2020 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2020

8. Researchers Submit Patent Application, 'Cells Expressing Recombinant Growth Factor Receptors', for Approval (USPTO 20200263130)

Subjects
Clinical trials, Biochemistry, Romiplostim -- Intellectual property, Eltrombopag -- Intellectual property, T cells, Business, Health, Health care industry
Abstract

2020 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors Bridgeman, John [...]

Published
2020

9. Patent Application Titled 'Uses Of Bcl-2 Antagonists For Treating Cancer And Diagnostics Related Thereto' Published Online (USPTO 20190328729)

Subjects
Cabazitaxel, Ixazomib, Ceritinib, Cobimetinib, Ruxolitinib -- Intellectual property, Acalabrutinib -- Intellectual property, Romiplostim -- Intellectual property, Siltuximab, Glucarpidase, Alectinib, Aminolevulinic acid -- Intellectual property, Midostaurin -- Intellectual property, BCR-ABL tyrosine kinase inhibitors, Ramucirumab, Trifluridine -- Intellectual property, Olaparib, Nivolumab, Carboplatin -- Intellectual property, Obinutuzumab, Lanreotide, Methylnaltrexone, Brigatinib -- Intellectual property, Rasburicase -- Intellectual property, Pamidronate -- Intellectual property, Axicabtagene ciloleucel -- Intellectual property, Enasidenib -- Intellectual property, Osimertinib, Palifermin -- Intellectual property, Cancer, Monoclonal antibodies, Pembrolizumab, Inotuzumab ozogamicin -- Intellectual property, Belinostat, Neratinib -- Intellectual property, Zoledronic acid, Decitabine, Copanlisib -- Intellectual property, Durvalumab -- Intellectual property, Palbociclib, Idelalisib, Blinatumomab, Bevacizumab -- Intellectual property, Antiemetics -- Intellectual property, Plerixafor, Abemaciclib -- Intellectual property, Eltrombopag -- Intellectual property, Talimogene laherparepvec, Antineoplastic agents -- Intellectual property, Afatinib, Temsirolimus, Cabozantinib, Fulvestrant, Pertuzumab, Dasatinib, Nelarabine, Axitinib, Ibrutinib, Sonidegib, Nilotinib, Abiraterone, Dabrafenib, Pemetrexed, Pomalidomide, Carfilzomib, Olaratumab, Enzalutamide, Sunitinib, Niraparib, Crizotinib, Necitumumab, Lapatinib, Dinutuximab, Ponatinib, Bosutinib, Rucaparib, Ofatumumab, Sorafenib, Bendamustine, Trametinib, Vemurafenib, Tumors, Ribociclib, Aflibercept, Panobinostat, Cancer treatment, Anopheles, Clofarabine, Ixabepilone, Vincristine, Editors, Lenvatinib, Rolapitant, Vandetanib, Aprepitant, Cetuximab, Atezolizumab, Romidepsin, Ipilimumab, Venetoclax, Trabectedin, Vismodegib, Elotuzumab, Pralatrexate, Regorafenib, Degarelix, Everolimus, Vorinostat, Avelumab, Palonosetron, Panitumumab, Brentuximab vedotin, Ibritumomab tiuxetan, Denosumab, Pazopanib, Daratumumab, Business, Health, Health care industry
Abstract

2019 NOV 19 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results